Anavar for Women is trending in 2025 as fitness-focused women seek safer, effective cutting support. Discover how Anvarol is ...

We expect to release the H1 2025 interim results of NTG Nordic Transport Group on the evening of August 11, 2025. A webcast and conference call will be held in the morning of August 12, 2025, at 10:00 ...

Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm ...

Menerals, a new men’s health supplement brand based in San Diego, has officially launched with a no-nonsense approach to restoring male vitality. Focused on foundational nutrition and fueled by trace ...

PhenQ has positioned itself as a leading best OTC fat-burning solution for men who want safe, structured weight support ...

Fulcrum granted the new employee 130,000 options to purchase shares of the company’s common stock at an exercise price of $7.02 per share, the closing price per share of Fulcrum’s common stock as ...

Profusa's Common Stock is Expected to Begin Trading on Nasdaq on Monday, July 14, 2025 Under the Ticker "PFSA" ...

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (Milestone) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the ...

This prestigious award recognizes a British Columbia-based biotechnology company demonstrating exceptional progress and achievement of key strategic milestones, attributes that reflect Variational ...

Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth ...

ISS and Glass Lewis are leading U.S. institutional voting advisory services that regularly publish analyses on public shareholder votes. Inmagene is a privately held, clinical stage biopharmaceutical ...

Milestone intends to use the net proceeds from the Offering, together with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead ...